Evaluate efficacy and safety of fingolimod 0.5 mg orally once daily versus placebo in chronic inflammatory demyelinating polyradiculoneuropathy

Registry ID

EUCTR2011-005280-24

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Pharma Services AG

Start date

2012-08-01

Completion date

2016-09-01

Last update

2026-08-16

Conditions

• Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

Summary

To evaluate the effect of fingolimod 0.5 mg daily compared with placebo on delaying disability progression, in patients with CIDP, measured by the time to the first confirmed worsening on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale. A confirmed worsening is defined as an increase by 1 point or more on the adjusted INCAT Disability Scale from the value at Baseline.

Locations

• , , Greece
• , , Belgium
• , , Poland
• , , Spain
• , , Germany
• , , Czechia
• , , Italy
• , , Netherlands
• , , UK

Related clinical trials

• An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Xembify versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

View on source registry